Highlights Gentian Diagnostics

Equities

GENT

NO0010748866

Market Closed - Oslo Bors Other stock markets 10:45:00 2024-05-31 am EDT			5-day change	1st Jan Change
42.8 ^NOK	+4.39%		+2.88%	+3.13%

Apr. 30	Gentian Diagnostics ASA Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 30	Transcript : Gentian Diagnostics ASA, Q1 2024 Earnings Call, Apr 30, 2024

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Gentian Diagnostics ASA Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 30	CI
Gentian Diagnostics ASA Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 09	CI
Gentian Diagnostics ASA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-26	CI
Gentian Diagnostics ASA Expands Product Portfolio With Turbidimetric Retinol-Binding Protein Immunoassay	23-09-29	CI
Gentian Diagnostics ASA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24	CI
Gentian Diagnostics ASA (OB:GENT) acquired Getica Ab from Erling Sundrehagen for SEK 2.8 million.	23-07-02	CI
Norway's Gentian Diagnostics Buys Sweden-based Getica in SEK3 Million Deal	23-06-15	MT
Gentian Diagnostics ASA (OB:GENT) entered into an agreement to acquire Getica Ab from Erling Sundrehagen for SEK 3 million.	23-06-14	CI
Gentian Diagnostics ASA Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
Gentian Diagnostics ASA Announces Results from Study on Health Economic Impact of Use of GCAL CalProtectin Immunoassay for Early Detection of Infection in Intensive Care Patients	23-03-22	CI
Gentian Diagnostics ASA Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-16	CI
Gentian Diagnostics ASA Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-16	CI
Gentian Diagnostics Asa Announces New Study Addresses the Use of Plasma Calprotectin in Sepsis Management	23-02-15	CI
Gentian Diagnostics ASA Receives Patent for NT-proBNP in the U.S	22-12-04	CI
Gentian Diagnostics ASA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-10-26	CI
Gentian Diagnostics ASA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-25	CI
Gentian Diagnostics ASA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-25	CI
Gentian Diagnostics Signs Distribution Deal for Renal Disease Testing Kit	22-08-23	MT
Gentian Diagnostics ASA Signs Distribution Agreement for Cystatin C	22-08-23	CI
Gentian Diagnostics AS Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-28	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Gentian Diagnostics

Equities

GENT

NO0010748866

Highlights

Filters